Fig 7.
Effect of EGFR, PI3K/Akt, and ERK1/2 inhibitors on cell proliferation. Supernatant levels of CXCL5 (A) and CXCL8 (B) produced from HepG2 and HCCLM3 cells treated with Erlotinib (EGFRI), U0126, BEZ235, or SHBM1009 for 1 hr followed by the stimulation with vehicle or epidermal growth factor at 50 or 100 ng/ml for 24 hr.